Updated Results of a Multicenter Phase I/IB Study of Umbralisib (TGR-1202) in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL

Drug Category :
Conference Category :
Lead Author : Davids M, et al.
Published Date : 14/06/2017
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Final%201202%20Ibrutinib%20ICML%20Davids.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top